Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the natural plant product berberine

Cell Cycle

Volumn 11, Issue 23, 2012, Pages 4447-4461

  Chappell, William H ^a   Abrams, Stephen L ^a   Franklin, Richard A ^a   LaHair, Michelle M ^a   Montalto, Giuseppe ^b,c   Cervello, Melchiorre ^c   Martelli, Alberto M ^d,e   Nicoletti, Ferdinando ^f   Candido, Saverio ^f   Libra, Massimo ^f   Polesel, Jerry ^g   Talamini, Renato ^g   Milella, Michele ^h   Tafuri, Agostino ⁱ   Steelman, Linda S ^a   McCubrey, James A ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

^b UNIVERSITY OF PALERMO   (Italy)

^c CNR   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^f UNIVERSITY OF CATANIA   (Italy)

^g CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^h REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

ⁱ SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

BCL 2; Berberine; Breast cancer; Calmodulin kinase; Colorectal cancer; EGFR; Inhibitor sensitivity; Lcn2; Lipocalins; NGAL; Rapamycin; Siderocalins; Targeted therapy

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; BERBERINE; DEFEROXAMINE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; N [2 [[N [3 (4 CHLOROPHENYL) 2 PROPENYL] N METHYLAMINO]METHYL]PHENYL] N (2 HYDROXYETHYL) 4 METHOXYBENZENESULFONAMIDE; NATURAL PRODUCT; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PROTEIN BCL 2; RAPAMYCIN;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CELL STRAIN MCF 7; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFECT; DRUG TARGETING; HUMAN; HUMAN CELL; MOLECULARLY TARGETED THERAPY; PROTEIN EXPRESSION; TREATMENT RESPONSE;

EID: 84870866737     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.22786     Document Type: Article

References (203)

1. Poulikakos PI, Rosen N. Mutant BRAF melanomas-dependence and resistance. Cancer Cell 2011; 19:11-5; PMID:21251612; http://dx.doi.org/10.1016/j.ccr.2011. 01.008.
2. Wagle N, Emery C, Berger MF, Davis MJ, Sawyer A, Pochanard P, et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol 2011; 29:3085-96; PMID:21383288; http://dx.doi.org/10. 1200/JCO.2010.33.2312.
3. Schmidt P, Abken H. The beating heart of melanomas: a minor subset of cancer cells sustains tumor growth. Oncotarget 2011; 2:313-20; PMID:21487158.
4. Koomen JM, Smalley KS. Using quantitative proteomic analysis to understand genotype specific intrinsic drug resistance in melanoma. Oncotarget 2011; 2:329-35; PMID:21505227.
5. Whittaker S, Kirk R, Hayward R, Zambon A, Viros A, Cantarino N, et al. Gatekeeper mutations mediate resistance to BRAF-targeted therapies. Sci Transl Med 2010; 2:35ra41; PMID:20538618; http://dx.doi.org/10.1126/scitranslmed. 3000758.
6. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010; 468:973-7; PMID:21107323; http://dx.doi.org/10.1038/nature09626.
7. Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 2011; 480:387-90; PMID:22113612; http://dx.doi.org/10.1038/ nature10662.
8. Smalley KS, Lioni M, Dalla Palma M, Xiao M, Desai B, Egyhazi S, et al. Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. Mol Cancer Ther 2008; 7:2876-83; PMID:18790768; http://dx.doi.org/10.1158/1535-7163.MCT-08-0431.
9. Corcoran RB, Dias-Santagata D, Bergethon K, Iafrate AJ, Settleman J, Engelman JA. BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. Sci Signal 2010; 3:ra84; PMID:21098728; http://dx.doi.org/10.1126/scisignal.2001148.
10. Shi H, Moriceau G, Kong X, Lee MK, Lee H, Koya RC, et al. Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun 2012; 3:724; PMID:22395615; http://dx.doi.org/10.1038/ncomms1727.
11. Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010; 468:968-72; PMID:21107320; http://dx.doi.org/10.1038/ nature09627.
12. Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla AK, et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 2010; 18:683-95; PMID:21156289; http://dx.doi.org/10.1016/j.ccr. 2010.11.023.
13. Paraiso KH, Xiang Y, Rebecca VW, Abel EV, Chen YA, Munko AC, et al. PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res 2011; 71:2750-60; PMID:21317224; http://dx.doi.org/10.1158/0008-5472.CAN-10-2954.
14. Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J, et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012; 487:500-4; PMID:22763439; http://dx.doi.org/10.1038/ nature11183.
15. Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 2012; 487:505-9; PMID:22763448; http://dx.doi.org/10.1038/ nature11249.
16. Shull AY, Latham-Schwark A, Ramasamy P, Leskoske K, Oroian D, Birtwistle MR, et al. Novel somatic mutations to PI3K pathway genes in metastatic melanoma. PLoS One 2012; 7:e43369; PMID:22912864; http://dx.doi.org/10.1371/journal.pone. 0043369.
17. Muller FL, Colla S, Aquilanti E, Manzo VE, Genovese G, Lee J, et al. Passenger deletions generate therapeutic vulnerabilities in cancer. Nature 2012; 488:337-42; PMID:22895339; http://dx.doi.org/10.1038/nature11331.
18. Chomel JC, Turhan AG. Chronic myeloid leukemia stem cells in the era of targeted therapies: resistance, persistence and long-term dormancy. Oncotarget 2011; 2:713-27; PMID:21946665.
19. Hochhaus A, La Rosée P, Müller MC, Ernst T, Cross NC. Impact of BCR-ABL mutations on patients with chronic myeloid leukemia. Cell Cycle 2011; 10:250-60; PMID:21220945; http://dx.doi.org/10.4161/cc.10.2.14537.
20. Dienstmann R, Martinez P, Felip E. Personalizing therapy with targeted agents in non-small cell lung cancer. Oncotarget 2011; 2:165-77; PMID:21444946.
21. Pratilas CA, Hanrahan AJ, Halilovic E, Persaud Y, Soh J, Chitale D, et al. Genetic predictors of MEK dependence in non-small cell lung cancer. Cancer Res 2008; 68:9375-83; PMID:19010912; http://dx.doi.org/10.1158/0008-5472.CAN-08- 2223.
22. Steelman LS, Navolanic P, Chappell WH, Abrams SL, Wong EW, Martelli AM, et al. Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells. Cell Cycle 2011; 10:3003-15; PMID:21869603; http://dx.doi.org/10.4161/cc.10.17.17119.
23. Abrams SL, Steelman LS, Shelton JG, Wong EW, Chappell WH, Bäsecke J, et al. The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy. Cell Cycle 2010; 9:1781-91; PMID:20436278; http://dx.doi.org/10.4161/cc.9.9.11483.
24. Steelman LS, Abrams SL, Shelton JG, Chappell WH, Bäsecke J, Stivala F, et al. Dominant roles of the Raf/MEK/ERK pathway in cell cycle progression, prevention of apoptosis and sensitivity to chemotherapeutic drugs. Cell Cycle 2010; 9:1629-38; PMID:20372086; http://dx.doi.org/10.4161/cc.9.8.11487.
25. McCubrey JA, Steelman LS, Kempf CR, Chappell WH, Abrams SL, Stivala F, et al. Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways. J Cell Physiol 2011; 226:2762-81; PMID:21302297; http://dx.doi.org/10.1002/jcp.22647.
26. Hafsi S, Pezzino FM, Candido S, Ligresti G, Spandidos DA, Soua Z, et al. Gene alterations in the PI3K/PTEN/AKT pathway as a mechanism of drug-resistance (review). Int J Oncol 2012; 40:639-44; PMID:22200790.
27. Steelman LS, Chappell WH, Abrams SL, Kempf RC, Long J, Laidler P, et al. Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging (Albany NY) 2011; 3:192-222; PMID:21422497.
28. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Montalto G, Cervello M, et al. Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response. Oncotarget 2012; 3:954-87; PMID:23006971.
29. Qiu W, Sahin F, Iacobuzio-Donahue CA, Garcia-Carracedo D, Wang WM, Kuo CY, et al. Disruption of p16 and activation of Kras in pancreas increase ductal adenocarcinoma formation and metastasis in vivo. Oncotarget 2011; 2:862-73; PMID:22113502.
30. Adams JR, Schachter NF-, Liu JC, Zacksenhaus E, Egan SE. Elevated PI3K signaling drives multiple breast cancer subtypes. Oncotarget 2011; 2:435-47; PMID:21646685.
31. Anderson DH. p85 plays a critical role in controlling flux through the PI3K/PTEN signaling axis through dual regulation of both p110 (PI3K) and PTEN. Cell Cycle 2010; 9:2055-6; PMID:20505341; http://dx.doi.org/10.4161/cc.9.11. 11926.
32. Sokolosky ML, Stadelman KM, Chappell WH, Abrams SL, Martelli AM, Stivala F, et al. Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy. Oncotarget 2011; 2:538-50; PMID:21730367.
33. Kandouz M, Haidara K, Zhao J, Brisson ML, Batist G. The EphB2 tumor suppressor induces autophagic cell death via concomitant activation of the ERK1/2 and PI3K pathways. Cell Cycle 2010; 9:398-407; PMID:20046096; http://dx.doi.org/10.4161/cc.9.2.10505.
34. Jiang Z, Jones R, Liu JC, Deng T, Robinson T, Chung PE, et al. RB1 and p53 at the crossroad of EMT and triple-negative breast cancer. Cell Cycle 2011; 10:1563-70; PMID:21502814; http://dx.doi.org/10.4161/cc.10.10.15703.
35. Lehn S, Fernö M, Jirström K, Rydén L, Landberg G. A non-functional retinoblastoma tumor suppressor (RB) pathway in premenopausal breast cancer is associated with resistance to tamoxifen. Cell Cycle 2011; 10:956-62; PMID:21358261; http://dx.doi.org/10.4161/cc.10.6.15074.
36. Musgrove EA, Sutherland RL. RB in breast cancer: differential effects in estrogen receptor-positive and estrogen receptor-negative disease. Cell Cycle 2010; 9:4607-15; PMID:21260944; http://dx.doi.org/10.4161/cc.9.23.13889.
37. Ertel A, Dean JL, Rui H, Liu C, Witkiewicz AK, Knudsen KE, et al. RB-pathway disruption in breast cancer: differential association with disease subtypes, disease-specific prognosis and therapeutic response. Cell Cycle 2010; 9:4153-63; PMID:20948315; http://dx.doi.org/10.4161/cc.9.20.13454.
38. Glazer RI. A new therapeutic basis for treating Li-Fraumeni Syndrome breast tumors expressing mutated TP53. Oncotarget 2010; 1:470-1; PMID:21317445.
39. Herbert BS, Chanoux RA, Liu Y, Baenziger PH, Goswami CP, McClintick JN, et al. A molecular signature of normal breast epithelial and stromal cells from Li-Fraumeni syndrome mutation carriers. Oncotarget 2010; 1:405-22; PMID:21311097.
40. Napoli M, Girardini JE, Piazza S, Del Sal G. Wiring the oncogenic circuitry: Pin1 unleashes mutant p53. Oncotarget 2011; 2:654-6; PMID:21926448.
41. Harris JL, Khanna KK. BRCA1 A-complex fine tunes repair functions of BRCA1. Aging (Albany NY) 2011; 3:461-3; PMID:21805697.
42. Dever SM, Golding SE, Rosenberg E, Adams BR, Idowu MO, Quillin JM, et al. Mutations in the BRCT binding site of BRCA1 result in hyper-recombination. Aging (Albany NY) 2011; 3:515-32; PMID:21666281.
43. Poon JS, Eves R, Mak AS. Both lipid- and protein-phosphatase activities of PTEN contribute to the p53-PTEN anti-invasion pathway. Cell Cycle 2010; 9:4450-4; PMID:21084866; http://dx.doi.org/10.4161/cc.9.22.13936.
44. Fidalgo da Silva E, Ansari SB, Maimaiti J, Barnes EA, Kong-Beltran M, Donoghue DJ, et al. The tumor suppressor tuberin regulates mitotic onset through the cellular localization of cyclin B1. Cell Cycle 2011; 10:3129-39; PMID:21900748; http://dx.doi.org/10.4161/cc.10.18.17296.
45. Searle JS, Li B, Du W. Targeting Rb mutant cancers by inactivating TSC2. Oncotarget 2010; 1:228-32; PMID:20706560.
46. Gómez-Baldó L, Schmidt S, Maxwell CA, Bonifaci N, Gabaldón T, Vidalain PO, et al. TACC3-TSC2 maintains nuclear envelope structure and controls cell division. Cell Cycle 2010; 9:1143-55; PMID:20237422; http://dx.doi.org/10.4161/cc.9.6.11018.
47. Bhatia B, Nahlé Z, Kenney AM. Double trouble: when sonic hedgehog signaling meets TSC inactivation. Cell Cycle 2010; 9:456-9; PMID:20081363; http://dx.doi.org/10.4161/cc.9.3.10532.
48. Kolesnichenko M, Vogt PK. Understanding PLZF: two transcriptional targets, REDD1 and smooth muscle α-actin, define new questions in growth control, senescence, self-renewal and tumor suppression. Cell Cycle 2011; 10:771-5; PMID:21311223; http://dx.doi.org/10.4161/cc.10.5.14829.
49. Campaner S, Doni M, Verrecchia A, Fagà G, Bianchi L, Amati B. Myc, Cdk2 and cellular senescence: Old players, new game. Cell Cycle 2010; 9:3655-61; PMID:20818171; http://dx.doi.org/10.4161/cc.9.18.13049.
50. Bansal R, Nikiforov MA. Pathways of oncogene-induced senescence in human melanocytic cells. Cell Cycle 2010; 9:2782-8; PMID:20676024; http://dx.doi.org/10.4161/cc.9.14.12251.
51. Miller KR, Kelley K, Tuttle R, Berberich SJ. HdmX overexpression inhibits oncogene induced cellular senescence. Cell Cycle 2010; 9:3376-82; PMID:20724842; http://dx.doi.org/10.4161/cc.9.16.12779.
52. Kosar M, Bartkova J, Hubackova S, Hodny Z, Lukas J, Bartek J. Senescence-associated heterochromatin foci are dispensable for cellular senescence, occur in a cell type- and insult-dependent manner and follow expression of p16(ink4a). Cell Cycle 2011; 10:457-68; PMID:21248468; http://dx.doi.org/10.4161/cc.10.3.14707.
53. Taylor JR, Lehmann BD, Chappell WH, Abrams SL, Steelman LS, McCubrey JA. Cooperative effects of Akt-1 and Raf-1 on the induction of cellular senescence in doxorubicin or tamoxifen treated breast cancer cells. Oncotarget 2011; 2:610-26; PMID:21881167.
54. Godlewski J, Bronisz A, Nowicki MO, Chiocca EA, Lawler S. microRNA-451: A conditional switch controlling glioma cell proliferation and migration. Cell Cycle 2010; 9:2742-8; PMID:20647762; http://dx.doi.org/10.4161/cc.9.14.12248.
55. Mavrakis KJ, Leslie CS, Wendel HG. Cooperative control of tumor suppressor genes by a network of oncogenic microRNAs. Cell Cycle 2011; 10:2845-9; PMID:21857153; http://dx.doi.org/10.4161/cc.10.17.16959.
56. Sayed D, Abdellatif M. AKT-ing via microRNA. Cell Cycle 2010; 9:3213-7; PMID:20814244; http://dx.doi.org/10.4161/cc.9.16.12634.
57. Radojicic J, Zaravinos A, Vrekoussis T, Kafousi M, Spandidos DA, Stathopoulos EN. MicroRNA expression analysis in triple-negative (ER, PR and Her2/neu) breast cancer. Cell Cycle 2011; 10:507-17; PMID:21270527; http://dx.doi.org/10.4161/cc.10.3.14754.
58. Ma S, Guan XY. MiRegulators in cancer stem cells of solid tumors. Cell Cycle 2011; 10:571-2; PMID:21311235; http://dx.doi.org/10.4161/cc.10.4.14772.
59. Valastyan S, Weinberg RA. miR-31: a crucial overseer of tumor metastasis and other emerging roles. Cell Cycle 2010; 9:2124-9; PMID:20505365; http://dx.doi.org/10.4161/cc.9.11.11843.
60. Oliveras-Ferraros C, Cufí S, Vazquez-Martin A, Torres-Garcia VZ, Del Barco S, Martin-Castillo B, et al. Micro(mi)RNA expression profile of breast cancer epithelial cells treated with the anti-diabetic drug metformin: induction of the tumor suppressor miRNA let-7a and suppression of the TGFβ-induced oncomiR miRNA-181a. Cell Cycle 2011; 10:1144-51; PMID:21368581; http://dx.doi.org/10.4161/cc.10.7.15210.
61. García JM, Silva J, Peña C, Garcia V, Rodríguez R, Cruz MA, et al. Promoter methylation of the PTEN gene is a common molecular change in breast cancer. Genes Chromosomes Cancer 2004; 41:117-24; PMID:15287024; http://dx.doi.org/10.1002/gcc.20062.
62. Wang L, Wang WL, Zhang Y, Guo SP, Zhang J, Li QL. Epigenetic and genetic alterations of PTEN in hepatocellular carcinoma. Hepatol Res 2007; 37:389-96; PMID:17441812; http://dx.doi.org/10.1111/j.1872-034X.2007.00042.x.
63. Chang S, Sharan SK. Epigenetic control of an oncogenic microRNA, miR-155, by BRCA1. Oncotarget 2012; 3:5-6; PMID:22403740.
64. Faber AC, Wong KK, Engelman JA. Differences underlying EGFR and HER2 oncogene addiction. Cell Cycle 2010; 9:851-2; PMID:20160489; http://dx.doi.org/10.4161/cc.9.5.11096.
65. Rudloff U, Samuels Y. A growing family: adding mutated Erbb4 as a novel cancer target. Cell Cycle 2010; 9:1487-503; PMID:20404484; http://dx.doi.org/10. 4161/cc.9.8.11239.
66. Raven JF, Williams V, Wang S, Tremblay ML, Muller WJ, Durbin JE, et al. Stat1 is a suppressor of ErbB2/Neu-mediated cellular transformation and mouse mammary gland tumor formation. Cell Cycle 2011; 10:794-804; PMID:21311224; http://dx.doi.org/10.4161/cc.10.5.14956.
67. Martinez-Outschoorn UE, Trimmer C, Lin Z, Whitaker-Menezes D, Chiavarina B, Zhou J, et al. Autophagy in cancer associated fibroblasts promotes tumor cell survival: Role of hypoxia, HIF1 induction and NF-κB activation in the tumor stromal microenvironment. Cell Cycle 2010; 9:3515-33; PMID:20855962; http://dx.doi.org/10.4161/cc.9.17.12928.
68. Pavlides S, Tsirigos A, Vera I, Flomenberg N, Frank PG, Casimiro MC, et al. Transcriptional evidence for the "Reverse Warburg Effect" in human breast cancer tumor stroma and metastasis: similarities with oxidative stress, inflammation, Alzheimer's disease, and "Neuron-Glia Metabolic Coupling". Aging (Albany NY) 2010; 2:185-99; PMID:20442453.
69. Martinez-Outschoorn UE, Prisco M, Ertel A, Tsirigos A, Lin Z, Pavlides S, et al. Ketones and lactate increase cancer cell "stemness," driving recurrence, metastasis and poor clinical outcome in breast cancer: achieving personalized medicine via Metabolo-Genomics. Cell Cycle 2011; 10:1271-86; PMID:21512313; http://dx.doi.org/10.4161/cc.10.8.15330.
70. Yan L, Borregaard N, Kjeldsen L, Moses MA. The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL. J Biol Chem 2001; 276:37258-65; PMID:11486009; http://dx.doi.org/10.1074/jbc.M106089200.
71. Roy R, Louis G, Loughlin KR, Wiederschain D, Kilroy SM, Lamb CC, et al. Tumor-specific urinary matrix metalloproteinase fingerprinting: identification of high molecular weight urinary matrix metalloproteinase species. Clin Cancer Res 2008; 14:6610-7; PMID:18927302; http://dx.doi.org/10.1158/1078-0432.CCR-08- 1136.
72. Yang J, Bielenberg DR, Rodig SJ, Doiron R, Clifton MC, Kung AL, et al. Lipocalin 2 promotes breast cancer progression. Proc Natl Acad Sci USA 2009; 106:3913-8; PMID:19237579; http://dx.doi.org/10.1073/pnas.0810617106.
73. Yang J, Moses MA. Lipocalin 2: a multifaceted modulator of human cancer. Cell Cycle 2009; 8:2347-52; PMID:19571677; http://dx.doi.org/10.4161/cc.8.15. 9224.
74. Bolignano D, Donato V, Lacquaniti A, Fazio MR, Bono C, Coppolino G, et al. Neutrophil gelatinase-associated lipocalin (NGAL) in human neoplasias: a new protein enters the scene. Cancer Lett 2010; 288:10-6; PMID:19540040; http://dx.doi.org/10.1016/j.can-let.2009.05.027.
75. Leng X, Wu Y, Arlinghaus RB. Relationships of lipocalin 2 with breast tumorigenesis and metastasis. J Cell Physiol 2011; 226:309-14; PMID:20857428; http://dx.doi.org/10.1002/jcp.22403.
76. Shen F, Hu Z, Goswami J, Gaffen SL. Identification of common transcriptional regulatory elements in interleukin-17 target genes. J Biol Chem 2006; 281:24138-48; PMID:16798734; http://dx.doi.org/10.1074/jbc.M604597200.
77. Matsuo S, Yamazaki S, Takeshige K, Muta T. Crucial roles of binding sites for NF-κB and C/EBPs in IkappaB-zeta-mediated transcriptional activation. Biochem J 2007; 405:605-15; PMID:17447895; http://dx.doi.org/10.1042/ BJ20061797.
78. Roudkenar MH, Kuwahara Y, Baba T, Roushandeh AM, Ebishima S, Abe S, et al. Oxidative stress induced lipocalin 2 gene expression: addressing its expression under the harmful conditions. J Radiat Res 2007; 48:39-44; PMID:17229997; http://dx.doi.org/10.1269/jrr.06057.
79. Iannetti A, Pacifico F, Acquaviva R, Lavorgna A, Crescenzi E, Vascotto C, et al. The neutrophil gelatinase-associated lipocalin (NGAL), a NF-κB-regulated gene, is a survival factor for thyroid neoplastic cells. Proc Natl Acad Sci USA 2008; 105:14058-63; PMID:18768801; http://dx.doi.org/10. 1073/pnas.0710846105.
80. Franklin RA, Rodriguez-Mora OG, Lahair MM, McCubrey JA. Activation of the calcium/calmodulin-dependent protein kinases as a consequence of oxidative stress. Antioxid Redox Signal 2006; 8:1807-17; PMID:16987033; http://dx.doi.org/10.1089/ars.2006.8.1807.
81. Martelli AM, Evangelisti C, Chappell W, Abrams SL, Bäsecke J, Stivala F, et al. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway. Leukemia 2011; 25:1064-79; PMID:21436840; http://dx.doi.org/10.1038/leu.2011.46.
82. Steelman LS, Franklin RA, Abrams SL, Chappell W, Kempf CR, Bäsecke J, et al. Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. Leukemia 2011; 25:1080-94; PMID:21494257; http://dx.doi.org/10.1038/leu.2011.66.
83. Barré B, Coqueret O, Perkins ND. Regulation of activity and function of the p52 NF-κB subunit following DNA damage. Cell Cycle 2010; 9:4795-804; PMID:21131783; http://dx.doi.org/10.4161/cc.9.24.14245.
84. Melvin A, Mudie S, Rocha S. Further insights into the mechanism of hypoxia-induced NF-κB. [corrected]. Cell Cycle 2011; 10:879-82; PMID:21325892; http://dx.doi.org/10.4161/cc.10.6.14910.
85. Bao G, Clifton M, Hoette TM, Mori K, Deng SX, Qiu A, et al. Iron traffics in circulation bound to a siderocalin (Ngal)-catechol complex. Nat Chem Biol 2010; 6:602-9; PMID:20581821; http://dx.doi.org/10.1038/nchembio.402.
86. Yu Y, Kovacevic Z, Richardson DR. Tuning cell cycle regulation with an iron key. Cell Cycle 2007; 6:1982-94; PMID:17721086; http://dx.doi.org/10.4161/ cc.6.16.4603.
87. Le NT, Richardson DR. Iron chelators with high antiproliferative activity up-regulate the expression of a growth inhibitory and metastasis suppressor gene: a link between iron metabolism and proliferation. Blood 2004; 104:2967-75; PMID:15251988; http://dx.doi.org/10.1182/blood-2004-05-1866.
88. Kovacevic Z, Richardson DR. The metastasis suppressor, Ndrg-1: a new ally in the fight against cancer. Carcinogenesis 2006; 27:2355-66; PMID:16920733; http://dx.doi.org/10.1093/carcin/bgl146.
89. Kovacevic Z, Fu D, Richardson DR. The iron-regulated metastasis suppressor, Ndrg-1: identification of novel molecular targets. Biochim Biophys Acta 2008; 1783:1981-92; PMID:18582504; http://dx.doi.org/10.1016/j.bbamcr.2008. 05.016.
90. Assinder SJ, Dong Q, Kovacevic Z, Richardson DR. The TGF-beta, PI3K/Akt and PTEN pathways: established and proposed biochemical integration in prostate cancer. Biochem J 2009; 417:411-21; PMID:19099539; http://dx.doi.org/10.1042/ BJ20081610.
91. Yu Y, Gutierrez E, Kovacevic Z, Saletta F, Obeidy P, Suryo Rahmanto Y, et al. Iron chelators for the treatment of cancer. Curr Med Chem 2012; 19:2689-702; PMID:22455580; http://dx.doi.org/10.2174/092986712800609706.
92. Buss JL, Greene BT, Turner J, Torti FM, Torti SV. Iron chelators in cancer chemotherapy. Curr Top Med Chem 2004; 4:1623-35; PMID:15579100; http://dx.doi.org/10.2174/1568026043387269.
93. Kell DB. Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. BMC Med Genomics 2009; 2:2; PMID:19133145; http://dx.doi.org/10.1186/1755-8794-2-2.
94. Sarafanov AG, Todorov TI, Centeno JA, Macias V, Gao W, Liang WM, et al. Prostate cancer outcome and tissue levels of metal ions. Prostate 2011; 71:1231-8; PMID:21271612; http://dx.doi.org/10.1002/pros.21339.
95. Guo W, Schlicht M, Kucynda T, Zhou P, Valyi-Nagy K, Kajdacsy-Balla A. Iron increases the invasiveness of prostate cancer cells in vitro: Mechanisms and inhibition by the antioxidant ebselen. Cancer Res 2012; 72(Supplement 1): http://dx.doi.org/10.1158/1538-7445.AM2012-4322.
96. Pavlides S, Tsirigos A, Migneco G, Whitaker-Menezes D, Chiavarina B, Flomenberg N, et al. The autophagic tumor stroma model of cancer: Role of oxidative stress and ketone production in fueling tumor cell metabolism. Cell Cycle 2010; 9:3485-505; PMID:20861672; http://dx.doi.org/10.4161/cc.9.17.12721.
97. Demaria M, Giorgi C, Lebiedzinska M, Esposito G, D'Angeli L, Bartoli A, et al. A STAT3-mediated metabolic switch is involved in tumour transformation and STAT3 addiction. Aging (Albany NY) 2010; 2:823-42; PMID:21084727.
98. Brazzolotto X, Andriollo M, Guiraud P, Favier A, Moulis JM. Interactions between doxorubicin and the human iron regulatory system. Biochim Biophys Acta 2003; 1593:209-18; PMID:12581865; http://dx.doi.org/10.1016/S0167-4889(02)00391- 9.
99. Davies NP, Suryo Rahmanto Y, Chitambar CR, Richardson DR. Resistance to the antineoplastic agent gallium nitrate results in marked alterations in intracellular iron and gallium trafficking: identification of novel intermediates. J Pharmacol Exp Ther 2006; 317:153-62; PMID:16373528; http://dx.doi.org/10.1124/jpet.105.099044.
100. Whitnall M, Howard J, Ponka P, Richardson DR. A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc Natl Acad Sci USA 2006; 103:14901-6; PMID:17003122; http://dx.doi.org/10.1073/pnas.0604979103.
101. Ganguly A, Chakraborty P, Banerjee K, Chatterjee S, Basu S, Sarkar A, et al. Iron N-(2-hydroxy acetophenone) glycinate (FeNG), a non-toxic glutathione depletor circumvents doxorubicin resistance in Ehrlich ascites carcinoma cells in vivo. Biometals 2012; 25:149-63; PMID:21915630; http://dx.doi.org/10.1007/ s10534-011-9493-7.
102. Monier F, Mollier S, Guillot M, Rambeaud JJ, Morel F, Zaoui P. Urinary release of 72 and 92 kDa gelatinases, TIMPs, N-GAL and conventional prognostic factors in urothelial carcinomas. Eur Urol 2002; 42:356-63; PMID:12361901; http://dx.doi.org/10.1016/S0302-2838(02)00350-0.
103. Smith ER, Zurakowski D, Saad A, Scott RM, Moses MA. Urinary biomarkers predict brain tumor presence and response to therapy. Clin Cancer Res 2008; 14:2378-86; PMID:18413828; http://dx.doi.org/10.1158/1078-0432.CCR-07-1253.
104. Roy R, Yang J, Moses MA. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol 2009; 27:5287-97; PMID:19738110; http://dx.doi.org/10.1200/JCO.2009.23.5556.
105. Schmidt C. Urine biomarkers may someday detect even distant tumors. J Natl Cancer Inst 2009; 101:8-10; PMID:19116386; http://dx.doi.org/10.1093/jnci/ djn482.
106. Leng X, Ding T, Lin H, Wang Y, Hu L, Hu J, et al. Inhibition of lipocalin 2 impairs breast tumorigenesis and metastasis. Cancer Res 2009; 69:8579-84; PMID:19887608; http://dx.doi.org/10.1158/0008-5472.CAN-09-1934.
107. Hu L, Hittelman W, Lu T, Ji P, Arlinghaus R, Shmulevich I, et al. NGAL decreases E-cadherin-mediated cell-cell adhesion and increases cell motility and invasion through Rac1 in colon carcinoma cells. Lab Invest 2009; 89:531-48; PMID:19308044; http://dx.doi.org/10.1038/labinvest.2009.17.
108. Sun Y, Yokoi K, Li H, Gao J, Hu L, Liu B, et al. NGAL expression is elevated in both colorectal adenoma-carcinoma sequence and cancer progression and enhances tumorigenesis in xenograft mouse models. Clin Cancer Res 2011; 17:4331-40; PMID:21622717; http://dx.doi.org/10.1158/1078-0432.CCR-11-0226.
109. Fernández CA, Yan L, Louis G, Yang J, Kutok JL, Moses MA. The matrix metalloproteinase-9/neutrophil gelatinase-associated lipocalin complex plays a role in breast tumor growth and is present in the urine of breast cancer patients. Clin Cancer Res 2005; 11:5390-5; PMID:16061852; http://dx.doi.org/10. 1158/1078-0432.CCR-04-2391.
110. Hu J, Van den Steen PE, Sang Q-X, Opdenakker G. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov 2007; 6:480-98; PMID:17541420; http://dx.doi.org/10.1038/nrd2308.
111. Bourguignon LY, Gunja-Smith Z, Iida N, Zhu HB, Young LJ, Muller WJ, et al. CD44v(3,8-10) is involved in cytoskeleton-mediated tumor cell migration and matrix metalloproteinase (MMP-9) association in metastatic breast cancer cells. J Cell Physiol 1998; 176:206-15; PMID:9618160; http://dx.doi.org/10.1002/(SICI) 1097-4652(199807)176:1〈206::AIDJCP22〉3.0.CO;2-3.
112. Yu Q, Stamenkovic I. Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. Genes Dev 1999; 13:35-48; PMID:9887098; http://dx.doi.org/10.1101/gad.13.1.35.
113. Abécassis I, Olofsson B, Schmid M, Zalcman G, Karniguian A. RhoA induces MMP-9 expression at CD44 lamellipodial focal complexes and promotes HMEC-1 cell invasion. Exp Cell Res 2003; 291:363-76; PMID:14644158; http://dx.doi.org/10.1016/j.yexcr.2003.08.006.
114. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002; 2:161-74; PMID:11990853; http://dx.doi.org/10.1038/nrc745.
115. Chappell WH, Abrams SL, Stadelman KM, LaHair MM, Franklin RA, Cocco L, et al. Increased NGAL (Lnc2) expression after chemotherapeutic drug treatment. Adv Bio Reg 2012; 53: In press.
116. Chappell WH, Abrams SL, Montano G, Cervello M, Martelli AM, Candido S, et al. Effects of ectopic expression of NGAL on doxorubicin sensitivity. Oncotarget 2012; 3:1236-45; PMID:23100449.
117. Bauer M, Eickhoff JC, Gould MN, Mundhenke C, Maass N, Friedl A. Neutrophil gelatinase-associated lipocalin (NGAL) is a predictor of poor prognosis in human primary breast cancer. Breast Cancer Res Treat 2008; 108:389-97; PMID:17554627; http://dx.doi.org/10.1007/s10549-007-9619-3.
118. Salzano M, Rusciano MR, Russo E, Bifulco M, Postiglione L, Vitale M. Calcium/calmodulin-dependent protein kinase II (CaMKII) phosphorylates Raf-1 at serine 338 and mediates Ras-stimulated Raf-1 activation. Cell Cycle 2012; 11:2100-6; PMID:22592532; http://dx.doi.org/10.4161/cc.20543.
119. Howe CJ, LaHair MM, Maxwell JA, Lee JT, Robinson PJ, Rodriguez-Mora O, et al. Participation of the calcium/calmodulin-dependent kinases in hydrogen peroxide-induced Ikappa B phosphorylation in human T lymphocytes. J Biol Chem 2002; 277:30469-76; PMID:12063265; http://dx.doi.org/10.1074/jbc.M205036200.
120. Jensen TE, Rose AJ, Jørgensen SB, Brandt N, Schjerling P, Wojtaszewski JF, et al. Possible CaMKK-dependent regulation of AMPK phosphorylation and glucose uptake at the onset of mild tetanic skeletal muscle contraction. Am J Physiol Endocrinol Metab 2007; 292:E1308-17; PMID:17213473; http://dx.doi.org/10.1152/ajpendo.00456.2006.
121. Franklin RA, Rodriguez-Mora OG, Lahair MM, McCubrey JA. Activation of the calcium/calmodulin-dependent protein kinases as a consequence of oxidative stress. Antioxid Redox Signal 2006; 8:1807-17; PMID:16987033; http://dx.doi.org/10.1089/ars.2006.8.1807.
122. Rodriguez-Mora OG, Lahair MM, Evans MJ, Kovacs CJ, Allison RR, Sibata CH, et al. Inhibition of the CaM-kinases augments cell death in response to oxygen radicals and oxygen radical inducing cancer therapies in MCF-7 human breast cancer cells. Cancer Biol Ther 2006; 5:1022-30; PMID:16855386; http://dx.doi.org/10.4161/cbt.5.8.2910.
123. Rodriquez-Mora OG, LaHair MM, McCubrey JA, Franklin RA. CaM-KI and CAM-KK participate in the control of cell cycle progression in MCF-7 breast cancer cells. Cancer Res 2005; 65:5408-16; PMID:15958590; http://dx.doi.org/10.1158/ 0008-5472.CAN-05-0271.
124. Rongo C. Epidermal growth factor and aging: a signaling molecule reveals a new eye opening function. Aging (Albany NY) 2011; 3:896-905; PMID:21931179.
125. Cervello M, McCubrey JA, Cusimano A, Lampiasi N, Azzolina A, Montalto G. Targeted therapy for hepatocellular carcinoma: novel agents on the horizon. Oncotarget 2012; 3:236-60; PMID:22470194.
126. Ratajczak MZ, Kucia M, Liu R, Shin DM, Bryndza E, Masternak MM, et al. RasGrf1: genomic imprinting, VSELs, and aging. Aging (Albany NY) 2011; 3:692-7; PMID:21765200.
127. de Magalhães JP. A role for Ras signaling in modulating mammalian aging by the GH/IGF1 axis. Aging (Albany NY) 2011; 3:336-7; PMID:21512206.
128. Schmidt-Kittler O, Zhu J, Yang J, Liu G, Hendricks W, Lengauer C, et al. PI3Kα inhibitors that inhibit metastasis. Oncotarget 2010; 1:339-48; PMID:21179398.
129. Martelli AM, Tabellini G, Ricci F, Evangelisti C, Chiarini F, Bortul R, et al. PI3K/AKT/mTORC1 and MEK/ERK signaling in T-cell acute lymphoblastic leukemia: New options for targeted therapy. Adv Enzyme Regul 2011; In press; PMID:21983557.
130. Evangelisti C, Ricci F, Tazzari P, Tabellini G, Battistelli M, Falcieri E, et al. Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia. Leukemia 2011; 25:781-91; PMID:21331075; http://dx.doi.org/10.1038/leu.2011.20.
131. Martelli AM, Chiarini F, Evangelisti C, Cappellini A, Buontempo F, Bressanin D, et al. Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment. Oncotarget 2012; 3:371-94; PMID:22564882.
132. Bressanin D, Evangelisti C, Ricci F, Tabellini G, Chiarini F, Tazzari PL, et al. Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: eliminating activity by targeting at different levels. Oncotarget 2012; 3:811-23; PMID:22885370.
133. Garrett JT, Chakrabarty A, Arteaga CL. Will PI3K pathway inhibitors be effective as single agents in patients with cancer? Oncotarget 2011; 2:1314-21; PMID:22248929.
134. Markman B, Dienstmann R, Tabernero J. Targeting the PI3K/Akt/mTOR pathway - beyond rapalogs. Oncotarget 2010; 1:530-43; PMID:21317449.
135. Zawel L. P3Kα: a driver of tumor metastasis? Oncotarget 2010; 1:315-6; PMID:21307397.
136. Weber GL, Parat MO, Binder ZA, Gallia GL, Riggins GJ. Abrogation of PIK3CA or PIK3R1 reduces proliferation, migration, and invasion in glioblastoma multiforme cells. Oncotarget 2011; 2:833-49; PMID:22064833.
137. Agoulnik IU, Hodgson MC, Bowden WA, Ittmann MM. INPP4B: the new kid on the PI3K block. Oncotarget 2011; 2:321-8; PMID:21487159.
138. Dbouk HA, Backer JM. A beta version of life: p110βtakes center stage. Oncotarget 2010; 1:729-33; PMID:21321382.
139. Sacco A, Roccaro A, Ghobrial IM. Role of dual PI3/Akt and mTOR inhibition in Waldenstrom's Macroglobulinemia. Oncotarget 2010; 1:578-82; PMID:21317453.
140. Peng C, Chen Y, Li D, Li S. Role of Pten in leukemia stem cells. Oncotarget 2010; 1:156-60; PMID:21297225.
141. Antico Arciuch VG, Russo MA, Dima M, Kang KS, Dasrath F, Liao XH, et al. Thyrocyte-specific inactivation of p53 and Pten results in anaplastic thyroid carcinomas faithfully recapitulating human tumors. Oncotarget 2011; 2:1109-26; PMID:22190384.
142. Simioni C, Neri LM, Tabellini G, Ricci F, Bressanin D, Chiarini F, et al. Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia. Leukemia 2012; 26:2336-42; http://dx.doi.org/10.1038/ leu.2012.136; PMID:22614243.
143. Hou J, Lam F, Proud C, Wang S. Targeting Mnks for cancer therapy. Oncotarget 2012; 3:118-31; PMID:22392765.
144. Alinari L, Christian B, Baiocchi RA. Novel targeted therapies for mantle cell lymphoma. Oncotarget 2012; 3:203-11; PMID:22361516.
145. Major P. Potential of mTOR inhibitors for the treatment of subependymal giant cell astrocytomas in tuberous sclerosis complex. Aging (Albany NY) 2011; 3:189-91; PMID:21415462.
146. Aizman E, Mor A, Levy A, George J, Kloog Y. Ras inhibition by FTS attenuates brain tumor growth in mice by direct antitumor activity and enhanced reactivity of cytotoxic lymphocytes. Oncotarget 2012; 3:144-57; PMID:22323550.
147. Altman JK, Sassano A, Platanias LC. Targeting mTOR for the treatment of AML. New agents and new directions. Oncotarget 2011; 2:510-7; PMID:21680954.
148. Apontes P, Leontieva OV, Demidenko ZN, Li F, Blagosklonny MV. Exploring long-term protection of normal human fibroblasts and epithelial cells from chemotherapy in cell culture. Oncotarget 2011; 2:222-33; PMID:21447859.
149. Blagosklonny MV. Molecular damage in cancer: an argument for mTOR-driven aging. Aging (Albany NY) 2011; 3:1130-41; PMID:22246147.
150. Finkel T. Breathing lessons: Tor tackles the mitochondria. Aging (Albany NY) 2009; 1:9-11; PMID:20157592.
151. Leontieva OV, Blagosklonny MV. Yeast-like chronological senescence in mammalian cells: phenomenon, mechanism and pharmacological suppression. Aging (Albany NY) 2011; 3:1078-91; PMID:22156391.
152. Williamson DL. Normalizing a hyperactive mTOR initiates muscle growth during obesity. Aging (Albany NY) 2011; 3:83-4; PMID:21386136.
153. Blagosklonny MV. Progeria, rapamycin and normal aging: recent breakthrough. Aging (Albany NY) 2011; 3:685-91; PMID:21743107.
154. Panieri E, Toietta G, Mele M, Labate V, Ranieri SC, Fusco S, et al. Nutrient withdrawal rescues growth factor-deprived cells from mTOR-dependent damage. Aging (Albany NY) 2010; 2:487-503; PMID:20739737.
155. Leontieva OV, Blagosklonny MV. DNA damaging agents and p53 do not cause senescence in quiescent cells, while consecutive re-activation of mTOR is associated with conversion to senescence. Aging (Albany NY) 2010; 2:924-35; PMID:21212465.
156. Dulic V. Be quiet and you'll keep young: does mTOR underlie p53 action in protecting against senescence by favoring quiescence? Aging (Albany NY) 2011; 3:3-4; PMID:21248373.
157. Schug TT. mTOR favors senescence over quiescence in p53-arrested cells. Aging (Albany NY) 2010; 2:327-8; PMID:20603524.
158. Galluzzi L, Kepp O, Kroemer G. TP53 and MTOR crosstalk to regulate cellular senescence. Aging (Albany NY) 2010; 2:535-7; PMID:20876940.
159. Zhao C, Vollrath D. mTOR pathway activation in age-related retinal disease. Aging (Albany NY) 2011; 3:346-7; PMID:21483039.
160. Blagosklonny MV. Why men age faster but reproduce longer than women: mTOR and evolutionary perspectives. Aging (Albany NY) 2010; 2:265-73; PMID:20519781.
161. Blagosklonny MV. Why human lifespan is rapidly increasing: solving "longevity riddle" with "revealed-slow-aging" hypothesis. Aging (Albany NY) 2010; 2:177-82; PMID:20404395.
162. Maki CG. Decision-making by p53 and mTOR. Aging (Albany NY) 2010; 2:324-6; PMID:20603526.
163. Rosner M, Hengstschläger M. mTOR protein localization is cell cycle-regulated. Cell Cycle 2011; 10:3608-10; PMID:22024924; http://dx.doi.org/10.4161/cc.10.20.17855.
164. Jiang Y. mTOR goes to the nucleus. Cell Cycle 2010; 9:868; PMID:20348849; http://dx.doi.org/10.4161/cc.9.5.11070.
165. Lisse TS, Hewison M. Vitamin D: a new player in the world of mTOR signaling. Cell Cycle 2011; 10:1888-9; PMID:21558808; http://dx.doi.org/10.4161/ cc.10.12.15620.
166. Blagosklonny MV. Calorie restriction: decelerating mTOR-driven aging from cells to organisms (including humans). Cell Cycle 2010; 9:683-8; PMID:20139716; http://dx.doi.org/10.4161/cc.9.4.10766.
167. Armour SM, Baur JA, Hsieh SN, Land-Bracha A, Thomas SM, Sinclair DA. Inhibition of mammalian S6 kinase by resveratrol suppresses autophagy. Aging (Albany NY) 2009; 1:515-28; PMID:20157535.
168. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Montalto G, Cervello M, et al. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: Targeting these pathways for cancer treatment and overcoming therapy resistance. Oncotarget 2012; In press.
169. Grimaldi C, Chiarini F, Tabellini G, Ricci F, Tazzari PL, Battistelli M, et al. AMP-dependent kinase/mammalian target of rapamycin complex 1 signaling in T-cell acute lymphoblastic leukemia: therapeutic implications. Leukemia 2012; 26:91-100; PMID:21968881; http://dx.doi.org/10.1038/leu.2011.269.
170. Mancias JD, Kimmelman AC. Targeting autophagy addiction in cancer. Oncotarget 2011; 2:1302-6; PMID:22185891.
171. Vazquez-Martin A, Oliveras-Ferraros C, Cufí S, Del Barco S, Martin-Castillo B, Menendez JA. Metformin regulates breast cancer stem cell ontogeny by transcriptional regulation of the epithelial-mesenchymal transition (EMT) status. Cell Cycle 2010; 9:3807-14; PMID:20890129; http://dx.doi.org/10. 4161/cc.9.18.13131.
172. Shackelford DB, Shaw RJ. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer 2009; 9:563-75; PMID:19629071; http://dx.doi.org/10.1038/nrc2676.
173. van der Velden YU, Haramis AP. Insights from model organisms on the functions of the tumor suppressor protein LKB1: zebrafish chips in. Aging (Albany NY) 2011; 3:363-7; PMID:21721170.
174. Martelli AM, Chiarini F, Evangelisti C, Ognibene A, Bressanin D, Billi AM, et al. Targeting the liver kinase B1/AMP-activated protein kinase pathway as a therapeutic strategy for hematological malignancies. Expert Opin Ther Targets 2012; 16:729-42; PMID:22686561; http://dx.doi.org/10.1517/14728222.2012.694869.
175. Vakana E, Platanias LC. AMPK in BCR-ABL expressing leukemias. Regulatory effects and therapeutic implications. Oncotarget 2011; 2:1322-8; PMID:22249159.
176. Godlewski J, Bronisz A, Nowicki MO, Chiocca EA, Lawler S. microRNA-451: A conditional switch controlling glioma cell proliferation and migration. Cell Cycle 2010; 9:2742-8; PMID:20647762; http://dx.doi.org/10.4161/cc.9.14.12248.
177. Chen V, Shtivelman E. CC3/TIP30 regulates metabolic adaptation of tumor cells to glucose limitation. Cell Cycle 2010; 9:4941-53; PMID:21150275; http://dx.doi.org/10.4161/cc.9.24.14230.
178. Chiacchiera F, Simone C. The AMPK-FoxO3A axis as a target for cancer treatment. Cell Cycle 2010; 9:1091-6; PMID:20190568; http://dx.doi.org/10.4161/ cc.9.6.11035.
179. Guo D, Cloughesy TF, Radu CG, Mischel PS. AMPK: A metabolic checkpoint that regulates the growth of EGFR activated glioblastomas. Cell Cycle 2010; 9:211-2; PMID:20023392; http://dx.doi.org/10.4161/cc.9.2.10540.
180. Saha AK, Xu XJ, Balon TW, Brandon A, Kraegen EW, Ruderman NB. Insulin resistance due to nutrient excess: is it a consequence of AMPK downregulation? Cell Cycle 2011; 10:3447-51; PMID:22067655; http://dx.doi.org/10.4161/cc.10.20. 17886.
181. Amato S, Man HY. Bioenergy sensing in the brain: the role of AMP-activated protein kinase in neuronal metabolism, development and neurological diseases. Cell Cycle 2011; 10:3452-60; PMID:22067656; http://dx.doi.org/10.4161/cc.10.20.17953.
182. Mounier R, Lantier L, Leclerc J, Sotiropoulos A, Foretz M, Viollet B. Antagonistic control of muscle cell size by AMPK and mTORC1. Cell Cycle 2011; 10:2640-6; PMID:21799304; http://dx.doi.org/10.4161/cc.10.16.17102.
183. Vazquez-Martin A, Oliveras-Ferraros C, Cufí S, Menendez JA. Polo-like kinase 1 regulates activation of AMP-activated protein kinase (AMPK) at the mitotic apparatus. Cell Cycle 2011; 10:1295-302; PMID:21474997; http://dx.doi.org/10.4161/cc.10.8.15342.
184. Anisimov VN, Berstein LM, Popovich IG, Zabezhinski MA, Egormin PA, Piskunova TS, et al. If started early in life, metformin treatment increases life span and postpones tumors in female SHR mice. Aging (Albany NY) 2011; 3:148-57; PMID:21386129.
185. Del Barco S, Vazquez-Martin A, Cufí S, Oliveras-Ferraros C, Bosch-Barrera J, Joven J, et al. Metformin: multi-faceted protection against cancer. Oncotarget 2011; 2:896-917; PMID:22203527.
186. Menendez JA, Cufí S, Oliveras-Ferraros C, Martin-Castillo B, Joven J, Vellon L, et al. Metformin and the ATM DNA damage response (DDR): accelerating the onset of stress-induced senescence to boost protection against cancer. Aging (Albany NY) 2011; 3:1063-77; PMID:22170748.
187. Halicka HD, Zhao H, Li J, Traganos F, Zhang S, Lee M, et al. Genome protective effect of metformin as revealed by reduced level of constitutive DNA damage signaling. Aging (Albany NY) 2011; 3:1028-38; PMID:22067284.
188. Gomes AP, Duarte FV, Nunes P, Hubbard BP, Teodoro JS, Varela AT, et al. Berberine protects against high fat diet-induced dysfunction in muscle mitochondria by inducing SIRT1-dependent mitochondrial biogenesis. Biochim Biophys Acta 2012; 1822:185-95; PMID:22027215; http://dx.doi.org/10.1016/j. bbadis.2011.10.008.
189. Zhao HL, Sui Y, Qiao CF, Yip KY, Leung RK, Tsui SK, et al. Sustained antidiabetic effects of a berberine-containing Chinese herbal medicine through regulation of hepatic gene expression. Diabetes 2012; 61:933-43; PMID:22396199; http://dx.doi.org/10.2337/db11-1164.
190. Kim HS, Kim MJ, Kim EJ, Yang Y, Lee MS, Lim JS. Berberine-induced AMPK activation inhibits the metastatic potential of melanoma cells via reduction of ERK activity and COX-2 protein expression. Biochem Pharmacol 2012; 83:385-94; PMID:22120676; http://dx.doi.org/10.1016/j.bcp.2011.11.008.
191. Gwinn DM, Shackelford DB, Egan DF, Mihaylova MM, Mery A, Vasquez DS, et al. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell 2008; 30:214-26; PMID:18439900; http://dx.doi.org/10.1016/j.molcel.2008.03.003.
192. Noto H, Goto A, Tsujimoto T, Noda M. Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS One 2012; 7:e33411; PMID:22448244; http://dx.doi.org/10.1371/journal.pone.0033411.
193. Del Barco S, Vazquez-Martin A, Cufí S, Oliveras-Ferraros C, Bosch-Barrera J, Joven J, et al. Metformin: multi-faceted protection against cancer. Oncotarget 2011; 2:896-917; PMID:22203527.
194. Richardson AD, Scott DA. Reversing the Warburg effect through stromal autophagy. Cell Cycle 2011; 10:2830-1; PMID:21869600; http://dx.doi.org/10.4161/ cc.10.17.16576.
195. Demaria M, Giorgi C, Lebiedzinska M, Esposito G, D'Angeli L, Bartoli A, et al. A STAT3-mediated metabolic switch is involved in tumour transformation and STAT3 addiction. Aging (Albany NY) 2010; 2:823-42; PMID:21084727.
196. Darnell JE Jr. STAT3, HIF-1, glucose addiction and Warburg effect. Aging (Albany NY) 2010; 2:890-1; PMID:21149895.
197. Cufí S, Vazquez-Martin A, Oliveras-Ferraros C, Martin-Castillo B, Joven J, Menendez JA. Metformin against TGFβ-induced epithelial-to- mesenchymal transition (EMT): from cancer stem cells to aging-associated fibrosis. Cell Cycle 2010; 9:4461-8; PMID:21088486; http://dx.doi.org/10.4161/ cc.9.22.14048.
198. Green AS, Chapuis N, Lacombe C, Mayeux P, Bouscary D, Tamburini J. LKB1/AMPK/mTOR signaling pathway in hematological malignancies: from metabolism to cancer cell biology. Cell Cycle 2011; 10:2115-20; PMID:21572254; http://dx.doi.org/10.4161/cc.10.13.16244.
199. Vazquez-Martin A, Oliveras-Ferraros C, Cufí S, Martin-Castillo B, Menendez JA. Metformin activates an ataxia telangiectasia mutated (ATM)/Chk2-regulated DNA damage-like response. Cell Cycle 2011; 10:1499-501; PMID:21566461; http://dx.doi.org/10.4161/cc.10.9.15423.
200. Mashhedi H, Blouin MJ, Zakikhani M, David S, Zhao Y, Bazile M, et al. Metformin abolishes increased tumor (18)F-2-fluoro-2-deoxy-D-glucose uptake associated with a high energy diet. Cell Cycle 2011; 10:2770-8; PMID:21811094; http://dx.doi.org/10.4161/cc.10.16.16219.
201. Oliveras-Ferraros C, Cufí S, Vazquez-Martin A, Torres-Garcia VZ, Del Barco S, Martin-Castillo B, et al. Micro(mi)RNA expression profile of breast cancer epithelial cells treated with the anti-diabetic drug metformin: induction of the tumor suppressor miRNA let-7a and suppression of the TGFβ-induced oncomiR miRNA-181a. Cell Cycle 2011; 10:1144-51; PMID:21368581; http://dx.doi.org/10.4161/cc.10.7.15210.
202. Martin-Castillo B, Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA. Metformin and cancer: doses, mechanisms and the dandelion and hormetic phenomena. Cell Cycle 2010; 9:1057-64; PMID:20305377; http://dx.doi.org/10.4161/ cc.9.6.10994.
203. Anisimov VN, Egormin PA, Piskunova TS, Popovich IG, Tyndyk ML, Yurova MN, et al. Metformin extends life span of HER-2/neu transgenic mice and in combination with melatonin inhibits growth of transplantable tumors in vivo. Cell Cycle 2010; 9:188-97; PMID:20016287; http://dx.doi.org/10.4161/cc.9.1. 10407.